Press Release: GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2
Press Release: GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2
Press Release: GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2
新聞稿：GlycoMimtics將於3月2日公佈2020年第四季度和年終財務業績
GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2
GlycoMimtics將於3月2日公佈2020年第四季度和年終財務業績
ROCKVILLE, Md.--(BUSINESS WIRE)--February 23, 2021--
馬里蘭州羅克維爾--(美國商業新聞網)--2021年2月23日--
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report fourth quarter and year-end 2020 financial results on Tuesday, March 2, 2021, at 8:30 a.m. ET.
亞洲網加利福尼亞州聖克拉拉3月2日電GlycoMimtics，Inc.(納斯達克市場代碼：GYC)今天宣佈，該公司將於2021年3月2日(星期二)上午8：30主持電話會議和網絡直播，公佈2020年第四季度和年終財務業績。Et.
The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1034166. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able to connect.
國內參會者的撥入號碼為(844)4137154，國際參會者的撥入號碼為(216)562-0466，參會者代碼為1034166。鼓勵參與者在通話前15分鐘接通，以確保所有呼叫者都能接通。
A webcast replay will be available via the "Investors" tab on the GlycoMimetics website for 30 days following the call. A dial-in phone replay will be available for 24 hours after the close of the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants, participant code 1034166.
電話會議結束後30天內，可通過GlycoMimtics網站上的“投資者”標籤收看網絡直播重播。在會議結束後的24小時內，國內參會者可撥打(855)8592056，國際參會者可撥打(4045373406)，參會者代碼為1034166。
About GlycoMimetics, Inc.
關於GlycoMimtics公司
GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including in a Company-sponsored Phase 3 trial in relapsed/refractory AML under Breakthrough Therapy Designation. Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in sickle cell disease. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
GlycoMimtics是一家生物技術公司，專注於血液腫瘤學和一系列新型仿糖藥物的流水線，所有這些藥物都是為了解決因碳水化合物生物學起關鍵作用的疾病而導致的未得到滿足的醫療需求。GlycoMimtics的候選藥物uproleselan是一種E-選擇素拮抗劑，在1/2期臨牀試驗中作為治療急性髓細胞白血病的潛在方法進行了評估，目前正在一系列患者中進行評估，其中包括公司贊助的突破性治療指定的復發/難治性急性髓細胞白血病的3期試驗。Rivipansel是一種泛選擇素拮抗劑，正在探索用於治療鐮狀細胞疾病的急性VOC。GlycoMimtics還完成了與另一種全資候選藥物GMI-1359的一期臨牀試驗，GMI-1359是一種CXCR4和E-選擇素聯合拮抗劑。GlycoMimtics公司位於馬里蘭州羅克維爾，位於生物健康首都地區。欲瞭解更多信息，請訪問www.garcomimetics.com。
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223006084/en/
在business wire.com上查看源代碼版本：https://www.businesswire.com/news/home/20210223006084/en/
CONTACT: Investors:
聯繫人：投資者：
Shari Annes
莎莉·安尼斯(Shari Annes)
Phone: 650-888-0902
電話：650-888-0902
Email: sannes@annesassociates.com
電子郵件：sannes@annesAssociates.com
Media:
媒體：
Jamie Lacey-Moreira
傑米·萊西-莫雷拉
Phone: 410-299-3310
電話：410-299-3310
Email: jamielacey@presscommpr.com
電子郵件：jamielacey@presscommpr.com
(END) Dow Jones Newswires
(完)道瓊通訊社
February 23, 2021 16:41 ET (21:41 GMT)
2021年2月23日美國東部時間16：41(格林尼治標準時間21：41)
譯文內容由第三人軟體翻譯。